Comirnaty: European Medicines Agency (EMA) recommends approval of adapted COVID-19 vaccine targeting Omicron XBB. 1.5
25 August 2023 – EMA’s human medicines committee has recommended authorising an adapted Comirnaty vaccine targeting the Omicron XBB.1.5 subvariant. The vaccine – known as Comirnaty Omicron XBB.1.5 – is to be used for preventing COVID-19 in adults and children from six months of age.
For more information, see here.